Schellenberg Wittmer advised Bioventure Club Deal Nine GmbH & Co KG on a Series B Financing Round of the Swiss Aphaia Companies, which are clinical stage pharma companies that have developed proprietary treatment methods targeting obesity and associated metabolic diseases.